Skip to main content
Mathew Cherian, MD, Oncology, Columbus, OH

MathewACherianMD

Oncology Columbus, OH

Physician

Dr. Cherian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Cherian's full profile

Already have an account?

  • Office

    1145 Olentangy River Rd
    Columbus, OH 43212
    Phone+1 614-293-0066
    Fax+1 614-293-7264

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2009 - 2012
  • University of North Dakota
    University of North DakotaResidency, Internal Medicine, 2003 - 2006
  • Christian Medical College Vellore
    Christian Medical College VelloreClass of 2000

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2018 - 2025
  • IL State Medical License
    IL State Medical License 2018 - 2020
  • MO State Medical License
    MO State Medical License 2009 - 2019
  • ND State Medical License
    ND State Medical License 2003 - 2009
  • MN State Medical License
    MN State Medical License 2006 - 2008
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Paul Calabresi NIH K12 Oncology Award 2016
  • American Society of Hematology Research Training Award for Fellows 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • An Activating Mutation of Interferon Regulatory Factor 4 (IRF4) in Adult T Cell Leukemia  
    Cherian MA, Olson S, Sundaramoorthi H, Cates K, Cheng X, Harding J, Martens A, Challen GA, Tyagi M, Ratner L, Rauch D, J Biol Chem, 1/14/2018
  • The Role of Neratinib in HER2 Driven Breast Cancer  
    Cherian MA, Ma CX, Future Oncol, 1/20/2017
  • A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome  
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R, Leuk Lymphoma, 1/1/2016
  • Join now to see all